Your browser doesn't support javascript.
Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.
Fryatt, Arun; Simms, Victoria; Bandason, Tsitsi; Redzo, Nicol; Olaru, Ioana D; Ndhlovu, Chiratidzo E; Mujuru, Hilda; Rusakaniko, Simbarashe; Hoelscher, Michael; Rubio-Acero, Raquel; Paunovic, Ivana; Wieser, Andreas; Chonzi, Prosper; Masunda, Kudzai; Ferrand, Rashida A; Kranzer, Katharina.
  • Fryatt A; Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Simms V; Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Bandason T; MRC International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Redzo N; Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Olaru ID; Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Ndhlovu CE; Biomedical Research and Training Institute, Harare, Zimbabwe.
  • Mujuru H; Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  • Rusakaniko S; Internal Medicine Unit, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe.
  • Hoelscher M; Department of Paediatrics and Child Health, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe.
  • Rubio-Acero R; Department of Community Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • Paunovic I; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
  • Wieser A; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Chonzi P; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
  • Masunda K; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
  • Ferrand RA; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
  • Kranzer K; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
EClinicalMedicine ; 41: 101172, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1474488
ABSTRACT

BACKGROUND:

By the end of July 2021 Zimbabwe, has reported over 100,000 SARS-CoV-2 infections. The true number of SARS-CoV-2 infections is likely to be much higher. We conducted a seroprevalence survey to estimate the prevalence of past SARS-CoV-2 in three high-density communities in Harare, Zimbabwe before and after the second wave of SARS-CoV-2.

METHODS:

Between November 2020 and April 2021 we conducted a cross-sectional study of randomly selected households in three high-density communities (Budiriro, Highfield and Mbare) in Harare. Consenting participants answered a questionnaire and a dried blood spot sample was taken. Samples were tested for anti-SARS-CoV-2 nucleocapsid antibodies using the Roche e801 platform.

FINDINGS:

A total of 2340 individuals participated in the study. SARS-CoV-2 antibody results were available for 70·1% (620/885) and 73·1% (1530/2093) of eligible participants in 2020 and 2021. The median age was 22 (IQR 10-37) years and 978 (45·5%) were men. SARS-CoV-2 seroprevalence was 19·0% (95% CI 15·1-23·5%) in 2020 and 53·0% (95% CI 49·6-56·4) in 2021. The prevalence ratio was 2·47 (95% CI 1·94-3·15) comparing 2020 with 2021 after adjusting for age, sex, and community. Almost half of all participants who tested positive reported no symptoms in the preceding six months.

INTERPRETATION:

Following the second wave, one in two people had been infected with SARS-CoV-2 suggesting high levels of community transmission. Our results suggest that 184,800 (172,900-196,700) SARS-CoV-2 infections occurred in these three communities alone, greatly exceeding the reported number of cases for the whole city. Further seroprevalence surveys are needed to understand transmission during the current third wave despite high prevalence of past infections.

FUNDING:

GCRF, Government of Canada, Wellcome Trust, Bavarian State Ministry of Sciences, Research, and the Arts.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials / Risk factors Language: English Journal: EClinicalMedicine Year: 2021 Document Type: Article Affiliation country: J.eclinm.2021.101172

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials / Risk factors Language: English Journal: EClinicalMedicine Year: 2021 Document Type: Article Affiliation country: J.eclinm.2021.101172